Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | TNKS | O95271 | 2/20 | 0.60 |
| ▸ | PARP1 | P09874 | 2/20 | 0.60 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.60 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.51 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644987 | 0.86 | CYP1B1 (0.63) | MAOBTNKSPARP1TNKS2CYP1B1 | |
| SCHEMBL1645950 | 0.85 | EGFR (0.54) | MAOBTNKSPARP1TNKS2PARP2 | |
| SCHEMBL311324 | 0.85 | NPC1 (0.60) | MAOBTNKSCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13945258 | 0.85 | CYP1A2 (0.56) | MAOBTNKSPARP1TNKS2PARP2 | |
| SCHEMBL311674 | 0.85 | MAOB (0.63) | MAOBTNKSTNKS2CSNK2A2CSNK2B | |
| Hydrochloric Acid SCHEMBL1647034 | 0.84 | EGFR (0.52) | MAOBTNKSPARP1TNKS2PARP2 | |
| Hydrochloric Acid SCHEMBL1647048 | 0.84 | CYP1A2 (0.55) | MAOBTNKSPARP1TNKS2PARP2 | |
| SCHEMBL311467 | 0.82 | KDM4E (0.48) | TNKSPARP1TNKS2CSNK2A2CSNK2B | |
| SCHEMBL311707 | 0.82 | TNKS (0.63) | MAOBTNKSPARP1TNKS2PARP2 | |
| SCHEMBL1645853 | 0.82 | CYP1B1 (0.46) | MAOBTNKSPARP1TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314295-B1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX INC (CA) | 2015-01-28 | — | — | EP | disclosed |
| US-8410109-B2 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX CORP. (CA) | 2013-04-02 | — | — | US | disclosed |
| EP-2314295-A1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | Resverlogix, Inc (CA) | 2011-04-27 | — | — | EP | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
| EP-1909788-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | MAOB 2265/4885TNKS 2747/4885PARP1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.